Page 1

INTERIM REPORT Q1 2021 January - March 2021 US office opened in preparation of launch SIGNIFICANT EVENTS IN Q1 2021 ■ Presentation of the clinical development plan for Oncoral ■ Opening of US office in preparation for the planned launch of Mangoral Directed new share issue of SEK 200 million SIGNIFICANT EVENTS AFTER THE PERIOD EGM approval of the directed new share issue Issuance and repurchase of C - shares for share saving program ■ KEY RATIOS GROUP " Opening of the US office in New Jersey marks an important step in our Mangoral launch plans " Q1 ( Jan - Mar ) 2021 OPERATING RESULT ( SEKm ) -33.7 2020 -1.00 EARNINGS PER SHARE ( SEK ) -20.7 -22.9 -0.71 CASH FLOW FROM OPERATIONS ( SEKM ) -18.4 ASCELIA PHARMA Advancing Orphan Oncology 169.3 LIQUID ASSETS INCL . MARKETABLE SECURITIES ( SEKM ) 165.4